

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3981]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At consultation, stakeholders identified that costs incurred by hospital visits and time off work to receive treatment will have a more significant impact on people with lower incomes.

Stakeholders also identified issues with variability of access to treatments at present due to ineligibility for autologous stem cell transplant and renal impairment, as well as worse outcomes for people with High Cytogenetic Risk Abnormalities (HCRA) and 1q21 amplification when treated with DRd (daratumumab, lenalidomide and dexamethasone). However, these highlighted issues do not relate to protected characteristics and are therefore not classed as potential equalities issues.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE considers appraisal technologies within their marketing authorisation for the whole population. Stakeholders will have an opportunity to submit evidence on health inequalities. As part of the technology appraisal, the committee will consider the impact of recommendations on people with protected characteristics in conjunction with the principles that guide the development of NICE guidance and standards including the aim to reduce health inequalities, with the following caveats:

1. The committee must follow the processes and methods set out in the NICE health technology evaluation manual and are unable to divert from

these methods and processes for individual evaluations or they will risk introducing further inequalities.

2. In accordance with NICE's [social value judgement](#) principles, no priority is given based on individuals' income, social class, position in life or social roles in guidance developed for the NHS.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): ...Richard Diaz.....

Date: 29/08/2024